tiprankstipranks
Trending News
More News >
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
US Market

PMV Pharmaceuticals (PMVP) AI Stock Analysis

Compare
103 Followers

Top Page

PM

PMV Pharmaceuticals

(NASDAQ:PMVP)

Rating:40Underperform
Price Target:
PMV Pharmaceuticals faces significant challenges typical of a biotech firm in the pre-commercialization phase, with no revenue and high R&D costs leading to negative financials. The strong cash position offers some financial flexibility, but the lack of revenue and ongoing losses are significant concerns. Technical indicators suggest a bearish trend, and valuation metrics reflect the company's developmental stage. A path to commercialization is essential for improving financial health and investor confidence.
Positive Factors
Approval Strategy
The trial is enrolling a diverse population across 5 cohorts, expecting one-third ovarian patients, which aligns with an initial focus that could expedite approval.
Clinical Trials
Enrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy in TP53 Y220C and KRAS WT advanced solid tumors remains on track.
Financial Performance
PMV ended 2024 with $183.3M in cash, which should fund operations to end-2026.
Negative Factors
Clinical Risks
Risks include negative PC14586 clinical data, delays in moving candidates into advanced trials, and setbacks in later-stage studies.
Deployment Probability
There is a low probability of PC14586 monotherapy deployment in a tumor-agnostic fashion due to the minimum requirement criteria.

PMV Pharmaceuticals (PMVP) vs. SPDR S&P 500 ETF (SPY)

PMV Pharmaceuticals Business Overview & Revenue Model

Company DescriptionPMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
How the Company Makes MoneyPMV Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company focuses on advancing its pipeline of small-molecule therapies through clinical trials and aims to monetize these assets via out-licensing agreements, partnerships with larger pharmaceutical companies, or direct sales upon regulatory approval. Key revenue streams include milestone payments, royalties, and upfront fees from partnerships and collaborations, which are essential to funding ongoing research and development efforts. The company's financial success is closely tied to the successful advancement of its drug candidates through clinical trials and obtaining necessary regulatory approvals.

PMV Pharmaceuticals Financial Statement Overview

Summary
PMV Pharmaceuticals is in a typical pre-revenue phase for a biotech firm, focusing heavily on R&D. Despite strong cash reserves, the company faces high operational losses and negative cash flows, with no revenue generation. The low debt levels are a positive, but the decline in equity and assets is concerning for long-term sustainability.
Income Statement
20
Very Negative
PMV Pharmaceuticals has consistently reported zero revenue over the years, highlighting the typical operational phase of a biotech firm focused on R&D before product commercialization. The net income is negative, with increasing losses, indicating high operational expenses relative to non-existent revenues. The absence of revenue growth and weak profit margins reflect challenges in moving towards profitability.
Balance Sheet
55
Neutral
The company's balance sheet shows a strong equity position with significant cash reserves, providing a buffer against the continued losses. The debt-to-equity ratio is low due to minimal debt levels, which is a positive sign. However, the continuous decline in stockholders' equity and asset base over the years is a concern, indicating potential long-term sustainability issues if the trend continues without revenue generation.
Cash Flow
40
Negative
PMV Pharmaceuticals exhibits negative operating and free cash flows, consistent with its stage in the biotech lifecycle. While free cash flow has improved slightly, it remains negative, reflecting high operational cash usage. The lack of positive cash flow from operations indicates reliance on external financing to sustain operations, posing a risk if capital markets become less favorable.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
0.00-1.26M-650.00K-1.28M-318.00K
EBIT
-85.45M-80.13M-77.04M-58.29M-34.94M
EBITDA
-85.45M-78.88M-76.72M-57.99M-34.62M
Net Income Common Stockholders
-58.71M-68.96M-73.32M-57.85M-34.44M
Balance SheetCash, Cash Equivalents and Short-Term Investments
169.45M203.06M241.05M297.16M361.42M
Total Assets
191.29M252.15M270.31M331.57M365.53M
Total Debt
1.19M13.29M13.98M11.19M0.00
Net Debt
-39.69M-24.42M-94.32M-161.27M-361.42M
Total Liabilities
15.21M26.46M24.28M23.01M6.41M
Stockholders Equity
176.08M225.69M246.03M308.56M359.12M
Cash FlowFree Cash Flow
-51.94M-56.62M-71.74M-47.92M-32.89M
Operating Cash Flow
-51.28M-55.66M-63.76M-46.57M-32.74M
Investing Cash Flow
53.35M-50.55M-1.37M-143.58M27.91M
Financing Cash Flow
313.00K35.58M958.00K2.02M292.97M

PMV Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.90
Price Trends
50DMA
1.03
Negative
100DMA
1.22
Negative
200DMA
1.39
Negative
Market Momentum
MACD
-0.05
Negative
RSI
43.25
Neutral
STOCH
69.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 0.93, below the 50-day MA of 1.03, and below the 200-day MA of 1.39, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of 69.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMVP.

PMV Pharmaceuticals Risk Analysis

PMV Pharmaceuticals disclosed 77 risk factors in its most recent earnings report. PMV Pharmaceuticals reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

PMV Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$324.54M4.11-58.97%23.81%146.45%
53
Neutral
$5.24B3.07-43.58%2.80%16.87%-0.11%
50
Neutral
$74.51M-119.22%25.51%
43
Neutral
$75.99M-679.15%-56.88%-57.57%
41
Neutral
$102.85M-196.81%
40
Underperform
$48.36M-32.66%21.33%
CUCUE
40
Underperform
$50.45M-221.66%13.83%37.66%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PMVP
PMV Pharmaceuticals
0.90
-1.13
-55.67%
PDSB
PDS Biotechnology
1.58
-1.54
-49.36%
CTMX
CytomX Therapeutics
2.04
0.21
11.48%
CUE
Cue Biopharma
0.71
-1.03
-59.20%
STRO
Sutro Biopharma
0.84
-3.24
-79.41%
GUTS
Fractyl Health, Inc.
1.84
-5.72
-75.66%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.